FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379231306> ?p ?o ?g. }

• W4379231306 endingPage "B003" @default.
• W4379231306 startingPage "B003" @default.
• W4379231306 abstract "Abstract Androgen receptor (AR) remains active in castration-resistant prostate cancer (CRPC), and AR cistrome can become extensively reprogrammed with disease progression. Recent findings from our group and others have shown an association with non-canonical AR signature with resistance to enzalutamide. However, the complete mechanism is not fully revealed. EVI1 belongs to the zinc-finger transcription factor family, and overexpression of EVI1 is associated with poor patient outcomes. However, its role in the context of resistance to AR-targeted therapy remains unclear. Our preliminary data from ChIP-seq and GSEA analysis shows a significant enrichment of EVI1 target gene-set captured from annotated enzalutamide-resistant AR binding sites. Hypothesis: EVI1 cooperates in regulating the non-canonical AR activity associated with resistance to AR targeted therapy and blocking EVI1 may overcome resistance to target therapy. Methods : Using a PDX model of advanced enzalutamide-resistant CRPC, we performed single-cell ATAC-seq + gene expression multi-omic assay. Next, we determined the enrichment of canonical vs. non-canonical AR signatures across cell populations. Using motif analysis and transcription factor foot printing, we determine EVI1 (MECOM) motif z score and enrichment. Results: Our findings demonstrate enrichment of non-canonical AR signatures in distinct population of cells following exposure to enzalutamide. In addition, the subpopulation of cells enriched for non-canonical AR cistrome also exhibited high EVI1 (MECOM) motif z-scores. Conclusion : Our data suggests a potential link between EVI1 and non-canonical AR signaling. Ongoing mechanistic studies will provide insight mechanism by which EVI1 controls non canonical AR activity and its vulnerabilities. Citation Format: Surendra Gulla, Jonathan E. Bard, David J. VanderWeele, Kathleen Kelly, Remi Adelaiye-Ogala. EVI1 oncogenic role in non-canonical AR driven lethal prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Advances in Prostate Cancer Research; 2023 Mar 15-18; Denver, Colorado. Philadelphia (PA): AACR; Cancer Res 2023;83(11 Suppl):Abstract nr B003." @default.
• W4379231306 created "2023-06-04" @default.
• W4379231306 creator A5051054140 @default.
• W4379231306 creator A5052330723 @default.
• W4379231306 creator A5074499498 @default.
• W4379231306 creator A5074874280 @default.
• W4379231306 creator A5088006315 @default.
• W4379231306 date "2023-06-02" @default.
• W4379231306 modified "2023-10-15" @default.
• W4379231306 title "Abstract B003: EVI1 oncogenic role in non-canonical AR driven lethal prostate cancer" @default.
• W4379231306 doi "https://doi.org/10.1158/1538-7445.prca2023-b003" @default.
• W4379231306 hasPublicationYear "2023" @default.
• W4379231306 type Work @default.
• W4379231306 citedByCount "0" @default.
• W4379231306 crossrefType "journal-article" @default.
• W4379231306 hasAuthorship W4379231306A5051054140 @default.
• W4379231306 hasAuthorship W4379231306A5052330723 @default.
• W4379231306 hasAuthorship W4379231306A5074499498 @default.
• W4379231306 hasAuthorship W4379231306A5074874280 @default.
• W4379231306 hasAuthorship W4379231306A5088006315 @default.
• W4379231306 hasConcept C104317684 @default.
• W4379231306 hasConcept C121608353 @default.
• W4379231306 hasConcept C2776551883 @default.
• W4379231306 hasConcept C2780192828 @default.
• W4379231306 hasConcept C502942594 @default.
• W4379231306 hasConcept C54355233 @default.
• W4379231306 hasConcept C61367390 @default.
• W4379231306 hasConcept C70721500 @default.
• W4379231306 hasConcept C86339819 @default.
• W4379231306 hasConcept C86803240 @default.
• W4379231306 hasConceptScore W4379231306C104317684 @default.
• W4379231306 hasConceptScore W4379231306C121608353 @default.
• W4379231306 hasConceptScore W4379231306C2776551883 @default.
• W4379231306 hasConceptScore W4379231306C2780192828 @default.
• W4379231306 hasConceptScore W4379231306C502942594 @default.
• W4379231306 hasConceptScore W4379231306C54355233 @default.
• W4379231306 hasConceptScore W4379231306C61367390 @default.
• W4379231306 hasConceptScore W4379231306C70721500 @default.
• W4379231306 hasConceptScore W4379231306C86339819 @default.
• W4379231306 hasConceptScore W4379231306C86803240 @default.
• W4379231306 hasIssue "11_Supplement" @default.
• W4379231306 hasLocation W43792313061 @default.
• W4379231306 hasOpenAccess W4379231306 @default.
• W4379231306 hasPrimaryLocation W43792313061 @default.
• W4379231306 hasRelatedWork W2177175549 @default.
• W4379231306 hasRelatedWork W2927728931 @default.
• W4379231306 hasRelatedWork W3044054345 @default.
• W4379231306 hasRelatedWork W3135324733 @default.
• W4379231306 hasRelatedWork W3155718207 @default.
• W4379231306 hasRelatedWork W4361817127 @default.
• W4379231306 hasRelatedWork W4361823263 @default.
• W4379231306 hasRelatedWork W4361849260 @default.
• W4379231306 hasRelatedWork W4361849348 @default.
• W4379231306 hasRelatedWork W4362541970 @default.
• W4379231306 hasVolume "83" @default.
• W4379231306 isParatext "false" @default.
• W4379231306 isRetracted "false" @default.
• W4379231306 workType "article" @default.